Addiction is a condition of harmful craving to repeatedly have something or do something. People with addiction have no control over their actions. They have a strong desire for drugs, alcohol, or other substances despite having knowledge about risks associated with it. The consumption rate of an addictive substance is directly proportional to the damage it causes to the brain. Addiction is a destructive disorder with a comparatively high death rate and serious social consequences. Various organizations such as Ministry of Public Health in Tunisia, Public Health England, and Center for Disease Control and Prevention have taken initiatives to spread awareness about de-addiction which supports addicted person to quit smoking habit with the help of smoking cessation products such as Chantix and Zyan.
Retaining the patients in the opioid de-addiction program to quite addiction has become easy, as the disorder management is connected through digital technologies like ‘Reset Application’ that is mobile medical application system which delivers cognitive behavioral therapy in patients suffering from substance use disorder. These technologies are helpful to both patients as well as physician because the clinical management of the treatment is more convenient. This is expected to create a positive impact in the market. For instance, in 2017, the U.S. Food & Drug Administration (FDA) permitted marketing of the first mobile medical application to help treat substance use disorders (SUD). SUD occurs when an individual’s continuous use of drugs and/or alcohol causes clinically and functionally significant mental and physical impairment. The ‘Reset application’ is intended to be used with outpatient therapy to manage alcohol, cocaine, marijuana, and stimulant substance use disorder (SUD).
The global addiction treatment market is estimated to be valued at US$ XX million in 2021 and is expected to exhibit a CAGR of XX% over the forecast period (2021-2028).
Figure 1. Global Addiction Treatment Market Share (%), By Region, 2021
The increasing prevalence of addicted population is expected to drive the growth of the global addiction treatment market over the forecast period.
For instance, according to the Canadian Centre on Substance Use and Addiction, 2017, in Canada there were around 77,000 hospitalizations solely caused by excessive alcohol consumption in 2015–2016, compared to 75,000 hospitalizations for heart attacks in the same year.
|Base Year:||2020||Market Size in 2021:||US$ 8,297.0 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||5.3%||2028 Value Projection:||US$ 12,210.0 Mn|
Alkremes Plc., Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals, Titan Pharmaceuticals, Inc., Pfizer, Inc., GlaxoSmithKline plc., Johnson & Johnson, Perrigo Company plc., Cipla Limited, Hikma Pharmaceuticals Plc., Dr. Reddy’s Laboratories Limited, Indivior Inc., and Mylan N.V.
|Restraints & Challenges:||
Figure 2. Global Addiction Treatment Market Value (US$ Mn), By Drug Type, 2021
Rising initiatives by various organizations towards de-addiction is expected to drive the market growth over the forecast period.
Various government and private organizations are taking initiatives to spread awareness about nicotine de-addiction, which supports addicted person to quit smoking habit with the help of smoking cessation products.
For instance, in 2017, the Ministry of Public Health in Tunisia re-launched Yakfi’ quit smoking campaign to encourage its citizens to stop smoking. First Yakfi’ campaign was launched in 2016, in collaboration with Ministry of Public Health, the World Health Organization (WHO), and the International Telecommunication Union (ITU). Such initiatives taken by governments and other organizations are expected to propel the demand for smoking cessation products.
The increasing product launches and approvals are expected to drive the market growth over the forecast period.
For instance, in June 2018, Japan Tobacco International (JTI) a leading tobacco company in Japan launched Logic Pro, a nicotine-containing e-cigarette, in Switzerland.
Moreover, in 2018, Elite Pharmaceuticals, Inc. specializing in manufacturing generic drug products received the U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for methadone hydrochloride 5 mg and 10 mg tablets which can be used for maintenance of opioid addiction
Global Addiction Treatment Market – Impact of Coronavirus (Covid-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 258,830,438 cases and 5,174,646 deaths due to coronavirus disease (COVID-19) were reported till November , 2021, across the globe.
The COVID-19 pandemic and lockdown in various countries across the globe has influenced the financial status of addiction treatment market. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions.
Due to the social and economic changes occurred during the pandemic, People suffering from substance use disorders (SUD) are at crucial stage mentally because of unavoidable stress. Difficulties in treatment access and adherence have impacted the mental as well as physical condition of patients. The stress and unpredictability of COVID-19 have made negative impacts on people. Due to this, the cases of people suffering from anxiety and depression have increased as well as the rate of misuse of opioids and stimulants has increased.
As per the Centers for Disease Control and Prevention, as of June 2020, it is reported that 13% of Americans have started or increased substance use to deal with stress or emotions imbalance related to COVID-19. Overdoses have also raised from the pandemic. The primary driver of the increase in overdose deaths is found to be synthetic opioids overdose.
Global Addiction Treatment Market Restraint
The legalization and rising adoption of cannabis, patent losses, and medical devices to treat opioid addiction are the factors expected to hinder growth of the global addiction treatment market over the forecast period.
For instance, in May 2018, the U.S. Food & Drug Administration (FDA) launched an ‘Innovation challenge’ to encourage the development of innovative medical devices to combat opioid abuse crisis.
Moreover, in 2017, the U.S. Food and Drug Administration (FDA) granted a new indication to an electric stimulation device NSS-2 Bridge is a tiny electrical nerve stimulator to reduce the symptoms of opioid withdrawal.
Major players operating in the global addiction treatment market include Alkremes Plc., Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals, Titan Pharmaceuticals, Inc., Pfizer, Inc., GlaxoSmithKline plc, and Johnson & Johnson, Perrigo Company plc. Cipla Limited, Hikma Pharmaceuticals Plc., Dr. Reddy’s Laboratories Limited, Indivior Inc, and Mylan N.V.
Addiction is a chronic condition which gives rise to psychological and physical damage. People who suffer from an addiction have an uncontrollable desire and lack of resistance to use lethal substances or to involve in harmful activities in spite of knowing their negative effects on their lives. Indications of addiction differ from person to person. Some have serious symptoms, such as inability to stop using addictive substance, increased tolerance for such addictive substance, lack of control as well as physical and emotional withdrawal. Risk of developing an addiction can be minimized by avoiding illegal drugs and immediately looking for counselling in case of any mental health disorder. A person suffering from an addictive disorder needs access to treatment. In many cases treatment may continue for the rest of their life. As per the patient’s need, treatment plans for addictive disorders will frequently modify. Treatment options depend on various factors such as the type of addictive disorder, the duration and danger of use, and its impact on the individual.
According to the National Survey on Drug Use and Health, in the U.S., approximately 8.1 percent of the population need or undergo treatment for drug addiction.
The rising prevalence of addicted population, expanding drug product pipeline, and active involvement of generic manufacturers to provide cheaper drugs are the major factors that are expected to drive the growth of the global addiction treatment market over the forecast period.
For instance, manufacturers such as Insys Therapeutics (innovative Buprenorphine / Naloxone sublingual spray), BioCorRx, Inc. (Naltrexone Implant (BICX102)) have novel products in their pipeline for opioid and alcohol addiction treatment.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.